

DAFTAR PUSTAKA

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistic 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018; 68:394–424.
2. Kementerian Kesehatan RI. Situasi Penyakit Kanker. Jakarta: Pusat Data dan Informasi. ; 2015.
3. Brunnicardi FC, Anderson DK, Billiar TK, Dunn DL, Hunter JG. *Schwartz's Principles of Surgery.* 9th ed. The united state of America: The McGraw-Hill Companies; 2010:183–15
4. Bolis S, Cocoroccio E, Corti C, Ferreri MJ, Grillo G, Omodeo ES. Clinical implications, Safety, Efficacy of Recombinant Granulocyte - Colony Stimulating Factors and Pegylated Equivalen. *Epidemiology Biostatic Public Health.* 2013:1–16
5. Crawford J, Dale DC, Lyman GH. Chemotherapy induced neutropenia : risks, consequences, and new directions for its management. *Cancer.* 2004;228–37.
6. Kwok C. Management of side effects from chemotherapy. *The Hongkong Anti Cancer Society.* 2010;12–16.
7. Sharma A, Lokeshwar N. Febrile neutropenia in haematological malignancies. *J Postgrad Med.* 2005; 51: 42–48.
8. Lyman GH. *Neutropenia : Overview and current therapies.* Elsevier. 2008;29–32.
9. Weycker D, Malin J, Edelsberg J, Glass A, Gokhale M and Oster G. Cost of neutropenic complications of chemotherapy. *Ann Oncol.* 2008 Maret;454–60.
10. Caggiano, V; Weiss, RV; Rickert, TS; Linde-Zwirble, WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. *American Cancer Society.* 2005 May; 103:22–29.
11. Kuderer NM, Dale DC, Crawford J. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. *Cancer.* 2006; 2258–66.
12. Nordvig J, Aagard T, Daugaard G, Brown P, Lundgren J, Helleberg M. Febrile neutropenia and long-term risk of infection among patients treated with

chemotherapy for malignant disease. *Open Forum Infect Dis.* 2018 Oct; 5(10).

13. Rapoport BL, Aapro M, Paesmans M, Eeden VR, Smit T, Krendyukov A. Febrile neutropenia occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. *BMC Cancer.* 2018 Sep; 18; 9–17.
14. Krzemieniecki K, Sevela P, Erdkamp F, Smakal M, Schwenkglenks M, Puertas J. Neutropenia management and granulocyte colony stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy- finding from clinical practice. *Support Care Cancer.* 2014; 22:667–77.
15. Renner P, Milazzo S, Liu JP, Zwahlen M, Birkmann J, Horneber M. Primary prophylactic colony stimulating factors for the prevention of chemotherapy induced febrile neutropenia in breast cancer patient. *The Cochrane Collaboration.* 2012;1–8.
16. Ohno, R; Tomonaga, M; Kobayashi, T. Effect of granulocyte colony stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. *N Engl J Med.* 1990; 323:871–77.
17. Usuki K, Urabe A, Masaoka T, Ohno R, Mizoguchi H, Hamajima N, et al. Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study. *British Journal of Haematology.* 2002; 116: 103–12.
18. Amadori, S; Suci, S; Jehn, U. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase 3 study. 2005; 106:27–34.
19. Hartman LC, Tschetter LK, Habermann TM, Ebbert LP, Johnson PS, Mailiard. Granulocyte colony stimulating factor in severe chemotherapy induced febrile neutropenia. *N Engl J Med.* 1997; 336:1776–80.
20. Kavgaci H, Ozdemir F, Aydin F, Yavuz A, Yavuz M. Endogenous granulocyte colony stimulating factor levels in chemotherapy induced neutropenia and in neutropenia related with primary diseases. *J Exp Clin Cancer Res.* 2002; 21:475–9.

21. Nagata S, Fukunaga R. Granulocyte colony stimulating factor and its receptor. *Progress in growth factor research*. 1991; 3:131–41.
22. Terashi K, Oka M, Ohdo S, Furukubo T, Ikeda C, Fukuda M, Soda H. Close association between clearance of recombinant human GCSF and GCSF receptor on neutrophils in cancer patients. *Antimicrobial agents and chemotherapy*. 1999; 43:21–24.
23. Geijn VD, Gits J, Aarts LH, Heijmans C, and Touw IP. Granulocyte colony stimulating factor and its receptor in normal hematopoietic cell development and myeloid disease. *Rev Physiol Biochem Pharmacol*. 2003; 149: 53–71.
24. Nagata, S; M, Tsuchiya; S, Asano; O, Yamamoto; Y, Hirata; N, Kubota. The chromosomal gene structure and two mRNAs for human granulocyte colony stimultaing factor. *European Molecular Biology Organization Journal*. 1986;575–81.
25. Hill, C P; Osslund, T D; D, Eisenberg. The structure of granulocyte colony stimulating factor and its relationship to other growth factors. *Proceeding National Academic Science*. 1993;5167–71.
26. Watasari K, Asano S, Shirafuji N, Kodo H, Ozawa K, Takaku F. Serum granulocyte colony stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay. *Blood journal*. 1989; 73:117–22.
27. Colony stimulating factor 3 (Granulocyte). *GeneCard*. 2010.
28. Dessen, P. CSF3 (colony stimulating factor 3 (granulocyte)). *Atlas genetic oncology*. 2010.
29. Fiedler K, Brunner C. Mechanism controlling hematopoiesis. *Hematology Science and practice*. 2012;1–45.
30. John PG, John F, George MR, Frixos P, Bertil G, Daniel A. *Wintrobe's clinical hematology*. 12th ed.; 2012;128–50
31. Pinheiro D, Sunkel C. Mechanism of cell cycle control; 2012:4–17
32. Bhel C, Ziegler C. *Cell Cycle: the life cycle of a cell. Molecular mechanism and*

- implications for disease. 2014; 9–19.
33. Morgan, G. Chemotherapy and the cell cycle. *Clinical*. 2007;27–30.
 34. Goldwein JW, Vachani C. Chemotherapy: the basics. *Cancer resources for patient and healthcare professional*. 2014; 1–10
 35. Robinson A, Oijen MV. Replication, transcription and translation: mechanism insight from single molecule biochemical studies. *Nature reviews*. 2013; 1–12
 36. Taanman JW. The mitochondrial genome: structure, transcription, translation and replication. *Biochemica et biophysica*. 2003; 103–23.
 37. Jacobson CA, Berliner N, Greer JP, Arber DA, Glader B. Neutropenia. In *Wintrobe's Clinical Hematology*. 13th ed. Philadelphia; 2014; 1279–89.
 38. Kaushansky K, Lichtman MA, Prchal JT. Production, Distribution, and Fate of Neutrophils. In *Williams Hematology*. 9th ed. New York: McGraw-Hill; 2016;1–25
 39. Berliner N, Horwitz M, Loughran TP Jr. Congenital and acquired neutropenia. *Hematology Am Soc Hematol Educ Program*. 2004; 63–79.
 40. Craig. Toward quantitative systems pharmacology models of chemotherapy-induced neutropenia. *CPT Pharmacometrics Sys.Pharmacol*. 2017;6: 293–04.
 41. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. *Proc Natl Acad Sci*. 1990; 87: 6934–38.
 42. Cosman D. The hematopoietin receptor superfamily. *Cytokine*. 1993; 5:95–106.
 43. Bravo J, Heath JK. Receptor recognition by gp130 cytokines. *EMBO*. 200; 19: 2399–11.
 44. Kurth I, Horsten U, Pflanz S, Timmermann A, Kuster A, Dahmen H, Tacke I, Heinrich PC, Muller-Newen G. Importance of the membrane-proximal extracellular domains for activation of the signal transducer glycoprotein. *J Immunol*. 2000; 164: 273–82.
 45. Santini V, Scappini B, Indik ZK, Gozzini A, Rossi Ferrini P, Schreiber AD. The Carboxyterminal region of the granulocyte-colony stimulating factor receptor

transduces a phagocytic signal. *Blood*. 2003;1–8.

46. Fukunaga R, Seto Y, Mizushima S, Nagata S. Three different mRNAs encoding human granulocyte colony-stimulating factor receptor. *Proc Natl Acad Sci*. 1990; 87: 8702–06.
47. Crea, F; Giovannetti, E; Zinzani, P L; Danesi, R. Pharmacologic rationale for early GCSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization. *Critical Reviews in Oncology Hematology*. 2009;21–44.
48. Gridelli C, Aapro MS, Berreta GD. Role of colony stimulating factors (CSFs) in solid tumours. *Critical reviews in oncology hematology*. 2007;53–64.
49. Dunn, C J; Goa, K L. Lenograstim : an update of its phramacological properties and use in chemotherapy induced neutropenia and related clinical settings. *Drugs*. 2006;681–17.
50. Renwick W; Pattengell R; Green M. Use of filgrastim and pegfilgrastim to support delivery of chemotherapy. *Biodrugs*. 2009;175–86.
51. Vogel C; Carroll R; Tjuladin S; Wiens BL. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer : a multicenter, double-blind, placebo-controlled phase III study. *Journal of clinical oncology*. 2005; 1178–84.
52. Dahlan MS. Besar sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan. In.: Salemba Medika; 2013; 36–80.
53. Schelenz S, Giles D, Abdallah S. Epidemiology, management and economic impact of febril neutropenia in oncology patients receiving routine care at a regional UK cancer centre. *Ann Oncol*. 2012; 1889–93.
54. Okera M, Chan S, Darnede U, Larkin J, Popat S, Gilbert D. A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findings. *Br J Cancer*. 2011; 104(3): 407–12.
55. Henk VDB, Paulesen M, Teuff GL, Judson I, Genderblom H, Dirksen U. Impact of gender on efficacy and acute toxicity of alkylating agent based chemotherapy in ewing sarcoma. *European J of Cancer*. 2015; 51: 2453–64.

56. Cristina V, Mahachie J, Mauer M, Cunningham D, Roth A, Wagner AD. Gender and chemotherapy-related toxicity in colon cancer: an analysis of PETACC-3 trial conducted by the EORTC GI-group. *Annals of oncology*. 2016; 149–206.
57. Rahman OA. Impact of sex on chemotherapy toxicity and efficacy among patients with metastatic colorectal cancer; a pooled analysis of five randomized trials. *Clin. colorec.can*. 2018;1–6.
58. Davidson M, Wagner AD, Starling N, Rao S, Peckitt C, Kouvelakis K. Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: a pooled analysis of four randomised trials. *Annal of oncology*. 2018; 29: 421–24.
59. Sabine OP, Vera RZ. *Sex and gender aspects in clinical medicine*. Springer. 2012; 165–68.
60. Rasmy A, Amal A, Fotih S, Selwi W. Febrile neutropenia in cancer patient : epidemiology, microbiology, pathophysiology and management. *J Cancer Prev Curr Res*. 2016; 5(3): 1–8.
61. Jolis, Carabantes, Pernas, Santos S, Torres. Incidence of chemotherapy induced neutropenia and current practice of prophylaxis with granulocyte colony stimulating factors in cancer patients in Spain : a prospective, observational study. *Eur J Cancer Care*. 2013; 22(4): 513–21.
62. Jacob LA, Lakshmaiah KC, Govindbabu K, Suresh TM, Lokanatha D. Clinical and microbiological profile of febrile neutropenia in solid tumors and hematological malignancies at a tertiary cancer care centre in South India. *India J Cancer*. 2014; 51(4): 464–68.

